Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9597677 | 0.67 | GABRA1 (0.40) | — | |
| SCHEMBL4041731 | 0.64 | — | — | |
| SCHEMBL286536 | 0.60 | — | — | |
| SCHEMBL452158 | 0.60 | — | — | |
| SCHEMBL6807961 | 0.60 | SMN1; SMN2 (0.33) | TP53SMN1; SMN2 | |
| SCHEMBL938857 | 0.58 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL558333 | 0.58 | FFAR1 (0.32) | — | |
| SCHEMBL8611683 | 0.58 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL1258094 | 0.58 | MAOA (0.45) | — | |
| SCHEMBL21326065 | 0.57 | DAO (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276764-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | claimed |
| US-8178523-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-15 | — | — | US | claimed |
| US-20110020275-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| EP-2276764-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009120745-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | claimed |
| EP-2276764-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8178523-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110020275-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2276764-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120745-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-0835242-A1 | THIOAMIDES S-OXIDES FOR USE AS PESTICIDES | Novartis AG (CH) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997000859-A1 | THIOAMIDES S-OXIDES FOR USE AS PESTICIDES | NOVARTIS AG (CH) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020275-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | TP53 516/4885SMN1; SMN2 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.